Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients.
about
Stereotactic body radiotherapy in lung cancer: an updateComplications from Stereotactic Body Radiotherapy for Lung CancerRedesigning radiotherapy quality assurance: opportunities to develop an efficient, evidence-based system to support clinical trials--report of the National Cancer Institute Work Group on Radiotherapy Quality AssuranceNo clinically significant changes in pulmonary function following stereotactic body radiation therapy for early- stage peripheral non-small cell lung cancer: an analysis of RTOG 0236SBRT in operable early stage lung cancer patients.Influence of patient's physiologic factors and immobilization choice with stereotactic body radiotherapy for upper lung tumors.Proton SBRT for medically inoperable stage I NSCLC.The effect of CyberKnife therapy on pulmonary function tests used for treating non-small cell lung cancer: a retrospective, observational cohort pilot studyStereotactic body radiotherapy for chronic obstructive pulmonary disease patients undergoing or eligible for long-term domiciliary oxygen therapyManagement and postoperative outcome in primary lung cancer and heart disease co-morbidity: a systematic review and meta-analysis.Lung stereotactic ablative radiotherapy (SABR): dosimetric considerations for chest wall toxicityThe use of proton-beam therapy in the treatment of non-small-cell lung cancer.Is stereotactic ablative radiotherapy an alternative to surgery in operable stage I non-small cell lung cancer?Radiation pneumonitis after stereotactic radiation therapy for lung cancer.Pulmonary Function Changes After Radiotherapy for Lung or Esophageal Cancer: A Systematic Review Focusing on Dose-Volume Parameters.What is the current status of Stereotactic body radiotherapy for stage I non-small cell lung cancer?Stereotactic ablative radiotherapy (SABR) in operable early stage non-small cell lung cancer (NSCLC) patients: challenge to claim being undisputed gold standard.Parenchymal and Functional Lung Changes after Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer-Experiences from a Single Institution.Dosimetric impact of number of treatment fields in uniform scanning proton therapy planning of lung cancer.A prospective study of quality of life including fatigue and pulmonary function after stereotactic body radiotherapy for medically inoperable early-stage lung cancer.Evaluation of ray tracing and Monte Carlo algorithms in dose calculation and clinical outcomes for robotic stereotactic body radiotherapy of lung cancers.Heart rate recovery and survival in patients undergoing stereotactic body radiotherapy for treatment of early-stage lung cancer.Survival of localized NSCLC patients without active treatment or treated with SBRT.Comparative efficacy and toxicity of induction chemotherapy with concurrent stereotactic body radiotherapy and stereotactic body radiotherapy with subsequent chemotherapy in patients with clinical stage T1-3N0M0 non-small cell lung carcinoma.Stereotactic body radiotherapy for stage I non-small cell lung cancer.Practical methods for improving dose distributions in Monte Carlo-based IMRT planning of lung wall-seated tumors treated with SBRT.Lung density change after SABR: A comparative study between tri-Co-60 magnetic resonance-guided system and linear accelerator.
P2860
Q26781806-7C04510C-3E93-4A6F-91E5-31BAA683965DQ26995851-E1B202EF-2CFD-4D76-840C-358413DDD77CQ27026968-4F43C86A-FB65-4771-945B-6CB81AB27E0EQ33758565-C62711E4-D358-4F46-BAA4-6DAF0D4200C6Q35200592-42F3FBE8-8E91-4FEF-A437-8A414ED3CFA3Q35245587-D581AA8E-845A-4015-9E71-79289EE3E957Q35965653-667344C0-7FBF-4A4A-B758-0C4F170F3175Q36326386-33B84DA5-A686-4439-98DB-84499881E52CQ36451625-142638E3-3C96-43FF-9A61-1CAB29630799Q37027257-76FEDBC0-5AC2-4895-8985-CE4C1847FD1AQ37175657-801E7A5E-1622-438D-8ED1-830D9A6B0615Q38088273-811D122C-0498-4DB5-AD89-CE0CA442A1A3Q38233871-F3B9733C-0723-485B-BF0B-3F74AB38D147Q38256158-372A74C7-AE9A-4972-95DF-A4FCE32CB405Q38678310-BCC283D9-6383-4150-8FA2-4CA3490D5C31Q40342856-58160460-12E4-491F-932E-CE7E05D357A7Q41112569-A9DFB04B-BCD8-4BD8-9810-888C9C45C3EAQ42154657-98EA2171-3C79-47DA-92AF-F2B87AACD8CBQ43057931-1F90594D-6F86-469C-A9E8-4D73329BCDE2Q44011535-96F92DAE-B943-4723-9282-F06F63B00CF9Q47097838-771B37EC-3792-4CD9-87FD-E57A4903898EQ47142210-89E134EC-BD9B-4D25-ADE3-2650568FC786Q47275269-B3F784DD-2D8E-4071-A345-B3E53960E75EQ48316437-3847DD9C-D110-49D8-988A-2D98BFF9649CQ49356651-2DF0255B-6D09-44A7-ACBC-6172967542BCQ51300392-DEB1B641-D36B-4AF1-A9F0-47EB1058FE7AQ52613276-4ACF3CBB-57FE-46B0-8AE9-0E9D0627EAC9
P2860
Comprehensive analysis of pulmonary function Test (PFT) changes after stereotactic body radiotherapy (SBRT) for stage I lung cancer in medically inoperable patients.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Comprehensive analysis of pulm ...... medically inoperable patients.
@en
Comprehensive analysis of pulmonary function Test
@nl
type
label
Comprehensive analysis of pulm ...... medically inoperable patients.
@en
Comprehensive analysis of pulmonary function Test
@nl
prefLabel
Comprehensive analysis of pulm ...... medically inoperable patients.
@en
Comprehensive analysis of pulmonary function Test
@nl
P2093
P1476
Comprehensive analysis of pulm ...... medically inoperable patients
@en
P2093
Gregory M M Videtic
Kevin L Stephans
Mathew Kolar
Michael Machuzak
Peter Mazzone
Stephen M Gajdos
Toufik Djemil
P304
P356
10.1097/JTO.0B013E3181A99FF6
P577
2009-07-01T00:00:00Z